A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

February 24, 2020

Study Completion Date

February 24, 2020

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

RVT-1201

RVT-1201 600 mg immediate-release tablet

DRUG

Placebo

Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet

Trial Locations (23)

20037

George Washington Medical Faculty Associates - Pulmonary Hypertension Program, Washington D.C.

27710

Duke University Medical Center, Durham

32610

University of Florida, Gainesville

32803

Central Florida Pulmonary Group, P.A., Orlando

33014

San Marcus Research Clinic, Inc., Miami Lakes

40202

Kentuckiana Pulmonary Research Center, Louisville

44195

Cleveland Clinic, Cleveland

48336

Pulmonary Research Institute of Southeast Michigan, Farmington Hills

60637

University of Chicago Medical Center, Chicago

63110

Washington University School of Medicine, St Louis

70112

Louisiana State University Health Sciences Center, New Orleans

75390

University of Texas Southwestern Medical Center, Dallas

77030

University of Texas Health Science Center at Houston, McGovern Medical School, Houston

80045

University of Colorado, Aurora

85006

Pulmonary Associates, PA, Phoenix

93105

SBPA Research LLC, Santa Barbara

95817

University of California Davis Medical Center, Sacramento

97239

Oregon Health & Science University, Portland

02115

Boston Children's Hospital, Boston

01199

Baystate Medical Center, Springfield

T1Y6J4

University of Calgary, Calgary

T6G 2B7

University of Alberta, Edmonton

N6A 5W9

London Health Sciences Centre, London

All Listed Sponsors
collaborator

Altavant Sciences, Inc.

UNKNOWN

collaborator

PPD Development, LP

INDUSTRY

lead

Altavant Sciences GmbH

INDUSTRY